All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

Hepatology

Volumn 61, Issue 4, 2015, Pages 1127-1135

  Nelson, David R ^a   Cooper, James N ^b   Lalezari, Jacob P ^c   Lawitz, Eric ^d   Pockros, Paul J ^e   Gitlin, Norman ^f   Freilich, Bradley F ^g   Younes, Ziad H ^h   Harlan, William ⁱ   Ghalib, Reem ^j   Oguchi, Godson ^k   Thuluvath, Paul J ^l   Ortiz Lasanta, Grisell ^m   Rabinovitz, Mordechai ⁿ   Bernstein, David ^o   Bennett, Michael ^p   Hawkins, Trevor ^q   Ravendhran, Natarajan ^r   Sheikh, Aasim M ^s   Varunok, Peter ^t   Kowdley, Kris V ^u,x   Hennicken, Delphine ^v   Mcphee, Fiona ^v   Rana, Khurram ^v   Hughes, Eric A ^w   more..

^a UNIVERSITY OF FLORIDA   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

^c Quest Clinical Research   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e SCRIPPS CLINIC   (United States)

^f Atlanta Gastroenterology Associates   (United States)

^g Kansas City Research Institute   (United States)

^h Gastro One   (United States)

ⁱ Asheville Gastroenterology   (United States)

^j Texas Clinical Research Institute   (United States)

^k Midland Florida Clinical Research Center   (United States)

^l MERCY MEDICAL CENTER   (United States)

^m Fundacion de Investigacion de Diego Santurce   (Puerto Rico)

ⁿ UNIVERSITY OF PITTSBURGH   (United States)

^o DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^p Medical Associates Research Group   (United States)

^q Southwest CARE Center   (United States)

^r Digestive Disease Associates   (United States)

^s Georgia Cancer Specialists   (United States)

^t Premier Medical Group of the Hudson Valley   (United States)

^u VIRGINIA MASON MEDICAL CENTER   (United States)

^v BRISTOL MYERS SQUIBB   (United States)

^w BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

^x SWEDISH MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; URIDINE PHOSPHATE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST KIT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; TREATMENT FAILURE; TREATMENT REFUSAL; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TIME; VIROLOGY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; SOFOSBUVIR; TIME FACTORS; URIDINE MONOPHOSPHATE; YOUNG ADULT;

EID: 84925364974     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27726     Document Type: Article

References (24)

1. Pol S, Vallet-Pichard A, Corouge M. Treatment of hepatitis C virus genotype 3-infection. Liver Int 2014;34(Suppl 1):18-23.
2. Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011;31(Suppl 2):1-3.
3. Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011;18:e516-e522.
4. Larsen C, Bousquet V, Delarocque-Astagneau E, Pioche C, Roudot-Thoraval F, HCV Surveillance Steering Committee, et al. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France. J Med Virol 2010;82:1647-1654.
5. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Mullhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009;51:655-666.
6. McCombs J, Matsuda T, Tonnu-Mihara I, Saab S, Hines P, L'italien G, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a department of veterans affairs clinical registry. JAMA Intern Med 2014;174:204-212.
7. U.S. Food and Drug Administration. SOVALDI™ (sofosbuvir) prescribing information. 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204671s000lbl.pdf. Accessed on January 3, 2015.
8. European Medicines Agency. Sovaldi (sofosbuvir) summary of product characteristics. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf. Accessed on January 3, 2015.
9. U.S. Food and Drug Administration. PEGASYS (peginterferon alfa-2a) prescribing information. 2002. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s5204lbl.pdf. Accessed on January 3, 2015.
10. European Medicines Agency. Pegasys (peginterferon alfa-2a) summary of product characteristics. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000395/WC500039195.pdf. Accessed on January 3, 2015.
11. European Medicines Agency. Daklinza (daclatasvir) summary of product characteristics. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf. Accessed on January 3, 2015.
12. European Medicines Agency. Harvoni (ledipasvir and sofosbuvir) summary of product characteristics. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003850/WC500177995.pdf. Accessed on January 3, 2015.
13. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
14. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-1877.
15. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001.
16. U.S. Food and Drug Administration. Copegus (ribavirin) prescribing information. 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021511s020lbl.pdf. Accessed on January 3, 2015.
17. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-221.
18. Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA. In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother 2013;57:611-613.
19. Clinicaltrials.gov. Safety and efficacy study of daclatasvir 60mg, sofosbuvir 400mg, and ribavirin (dosed based upon weight) in subjects with chronic genotype 3 hepatitis C infection with or without prior treatment experience and compensated advanced cirrhosis for 12 or 16 weeks. 2015. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02319031. Accessed on January 3, 2015.
20. Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, et al. High efficacy of treatment with sofosbuvir+GS-5816±ribavirin for 12 weeks in treatment experienced patients with genotype 1 or 3 HCV infection [abstract]. Hepatology 2014;60(Suppl):297A.
21. Gane EJ, Hyland RH, An D, Svarovskaia ES, Pang PS, Symonds WT, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection [abstract]. Hepatology 2014;60(Suppl):LB-11.
22. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 2013;3:514-520.
23. Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol 2013;57:13-18.
24. TM (ledipasvir and sofosbuvir) prescribing information. 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205834s000lbl.pdf. Accessed on January 3, 2015.